Singapore markets closed
  • Straits Times Index

    3,173.91
    +9.05 (+0.29%)
     
  • Nikkei

    29,068.63
    +517.70 (+1.81%)
     
  • Hang Seng

    25,330.96
    +368.37 (+1.48%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • BTC-USD

    62,081.76
    +2,582.49 (+4.34%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • FTSE Bursa Malaysia

    1,598.28
    +5.76 (+0.36%)
     
  • Jakarta Composite Index

    6,633.34
    +7.22 (+0.11%)
     
  • PSE Index

    7,213.46
    +30.35 (+0.42%)
     

Global Advanced Non-squamous and squamous NSCLC Pipeline Landscape Report 2021 Featuring F. Hoffmann-La Roche & Sanofi (Tiragolumab & SAR408701) - ResearchAndMarkets.com

·3-min read

DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Advanced Non-squamous and squamous NSCLC - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Non-Squamous & Squamous NSCLC R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Non-Squamous & Squamous NSCLC.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Chapters

This segment of the Advanced Non-Squamous & Squamous NSCLC report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs

Tiragolumab (RG6058): F. Hoffmann-La Roche Ltd

Roche's drug candidate Tiragolumab is in the phase III stage of the drug development process. It is being developed for the first line NSCLC where the drug is being tested in combination with Tecentriq. Tiragolumab is a fully human monomclonal antibody which is designed to bind with TIGIT and inhibit the interaction between poliovirus receptor and TIGIT.

SAR408701: Sanofi

Sanofi's drug molecule SAR408701 is in the phase II stage of the drug development process. It is a monoclonal antibody which works as a tubulin inhibitor and CEACAM5 targeting antibody. It is being developed as a combination therapy.

Major Players in Advanced Non-Squamous & Squamous NSCLC

There are approx. 4+ key companies which are developing the therapies for Advanced Non-Squamous & Squamous NSCLC. The companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e. phase II include, Sanofi.

The report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Advanced Non-Squamous & Squamous NSCLC: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Non-Squamous & Squamous NSCLC therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Non-Squamous & Squamous NSCLC drugs.

Key Questions Answered

  • How many companies are developing Advanced Non-Squamous & Squamous NSCLC drugs?

  • How many Advanced Non-Squamous & Squamous NSCLC drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Non-Squamous & Squamous NSCLC?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Non-Squamous & Squamous NSCLC therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Advanced Non-Squamous & Squamous NSCLC and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • F. Hoffmann-La Roche Ltd

  • Sanofi

Key Products

  • Tiragolumab

  • SAR408701

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/cw2dm4

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005802/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting